Full-Time

Senior Machine Learning Scientist

Confirmed live in the last 24 hours

Freenome

Freenome

201-500 employees

Biotechnology company for early cancer detection

Compensation Overview

$173.8k - $263.2k/yr

+ Pre-IPO Equity + Cash Bonuses

Senior

Daly City, CA, USA

Hybrid role based in Brisbane, California headquarters (2-3 days per week in office) or remote.

Category
Applied Machine Learning
Deep Learning
Natural Language Processing (NLP)
AI & Machine Learning
Required Skills
LLM
Python
Tensorflow
Neural Networks
Pytorch
Machine Learning
Java
Natural Language Processing (NLP)
LangChain
C/C++
Requirements
  • PhD or equivalent research experience with an AI/DL emphasis and in a relevant, quantitative field such as Computer Science, Statistics, Mathematics, Computational Biology with a strong track record in natural language processing
  • 3+ years of postdoc or post-PhD industry experience achieving impactful results using relevant modeling techniques
  • Expertise, demonstrated by research publications or industry achievements, in applied machine learning, deep learning and complex multimodal data modeling
  • Extensive experience in working with DL models, LLMs, and multimodal foundation models
  • Extensive experience with training paradigms like supervised learning, self-supervised learning, and contrastive learning
  • Practical and theoretical understanding of fundamental ML models like generalized linear models, kernel machines, decision trees and forests, neural networks
  • Solid grasp of NLP techniques, including but not limited to named entity recognition (NER), text summarization, and question answering
  • Proficiency in a general-purpose programming language: Python (preferred), Java, C, C++, etc
  • Proficiency in one or more ML frameworks such as Pytorch, Tensorflow, and Jax; LLM specific frameworks like LangChain; and ML platforms like Hugging Face
  • Experience in ML analysis and developer tools like TensorBoard, MLflow or Weights & Biases
  • Excellent ability to communicate across disciplines, work collaboratively, and make progress in smaller steps via experimental iterations
  • A passion for innovation and demonstrated initiative in tackling new areas of research
Responsibilities
  • Independently pursue cutting edge research using advanced AI algorithms and LLMs to analyze EHR data, extracting relevant information for cancer detection
  • Stay abreast of the latest developments in LLMs for natural language processing (NLP) and apply these models directly or after fine-tuning for clinical data analysis at Freenome
  • Design and develop AI pipelines, working closely with ML engineers, to increase efficiency of biomedical and clinical data extraction, processing, and interpretation
  • Collaborate with clinical data scientists and informaticians to understand data requirements and ensure the accuracy and relevance of AI-generated insights
  • Collaborate with machine learning scientists to integrate EHR data with non-EHR data sources, such as genomics or proteomics data, building robust multimodal models for cancer detection
  • Lead the development and optimization of algorithms and models that leverage diverse data types, ensuring high accuracy and reliability and predictions
  • Take a mindful, transparent, and humane approach to your work
Desired Qualifications
  • Experience in leveraging LLMs for EHR or other RWD data in healthcare or diagnostics
  • Demonstrated experience in integrating diverse data types with EHR data for multimodal analysis
  • Experience with containerized cloud computing environments such as Docker in GCP, Azure, or AWS
  • Experience in a production software engineering environment, including the use of automated regression testing, version control, and deployment system

Freenome focuses on improving cancer detection through advanced blood tests. The company uses a multiomics approach, analyzing various biological data types, including genomics and proteomics, to find cancer markers in the blood. Its primary clients are healthcare providers and research institutions, and it generates revenue by selling these non-invasive diagnostic tests. Freenome is also involved in clinical trials and research collaborations. Recently, it secured $270 million in funding to enhance its colorectal cancer blood test and expand clinical trials. The company aims to foster a collaborative culture and prioritize diversity, equity, and inclusion while driving innovation in cancer diagnostics.

Company Size

201-500

Company Stage

Late Stage VC

Total Funding

$1.1B

Headquarters

San Francisco, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Recent $254 million funding boosts Freenome's clinical programs and platform capabilities.
  • Partnership with Walgreens enhances clinical trial diversity and robustness.
  • Acquisition of Oncimmune strengthens Freenome's immunodiagnostics and multiomics platform.

What critics are saying

  • Leadership change with new CEO Aaron Elliott may lead to strategic shifts.
  • Layoffs of 100 employees could impact morale and productivity.
  • Dependence on large-scale clinical trials poses risks if results are unfavorable.

What makes Freenome unique

  • Freenome uses a unique multiomics approach for early cancer detection.
  • The company focuses on non-invasive blood tests for proactive disease management.
  • Freenome's platform designs personalized health conditions based on cell-free genome analysis.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Competitive market-based salaries

Annual bonus opportunities

Relocation packages

Medical, dental, & vision coverage

401k

Wellness programs

Equity

PTO

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

4%
PR Newswire
Apr 14th, 2025
Freenome Names Aaron Elliott, Ph.D., As Chief Executive Officer To Lead The Company'S Next Chapter Of Commercial Growth And Product Innovation

Accomplished industry leader brings specialized experience to advance Freenome's screening blood tests for colorectal cancer, lung cancer and additional indications BRISBANE, Calif., April 8, 2025 /PRNewswire/ -- Freenome, a biotechnology company pioneering an early cancer detection platform, today announced the appointment of Aaron Elliott, Ph.D., as its new chief executive officer. With nearly 20 years in the diagnostics industry, Aaron has provided leadership at the intersection of RD, product development and commercialization to drive market traction and expand clinical impact. His experience includes a deep focus on early cancer detection and multiomics that aligns with Freenome's mission to make cancer screening accessible for everyone

SDBN
Apr 24th, 2024
Cancer testing company Freenome to lay off 100 employees

Cancer testing company Freenome to lay off 100 employees.

GlobalData
Apr 14th, 2024
Freenome swings $254m investment

The announcement comes alongside two ongoing clinical trials launched by Freenome, including its prospective PREEMPT CRC study (NCT04369053), a longitudinal real-world data study consisting of under 40,000 participants evaluating the company's blood-based screening test among adults at average risk for CRC.

Freenome
Feb 16th, 2024
Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection | Freenome

Roche led the financing alongside existing and new investors. The funds will progress clinical programs and expand platform capabilities.

PR Newswire
Dec 12th, 2023
Freenome Initiates Proact Lung Clinical Study For The Early Detection Of Lung Cancer Using Blood Test Developed On Multiomics Platform

– Registrational study targets enrollment of 20,000 individuals at high risk of lung cancer –SOUTH SAN FRANCISCO, Calif., Dec. 12, 2023 /PRNewswire/ -- Freenome, a privately held company developing multiomics blood tests for early cancer detection, today announced the initiation of its PROACT LUNG study and provided an update on its lung cancer research, including the ongoing Vallania study. The study is intended to validate the clinical performance of the Freenome blood test for lung cancer screening. The test combines lung cancer-specific biomarkers with cancer-common markers identified on Freenome's proprietary multiomics platform. This is Freenome's second blood-based test developed on the platform and being evaluated in a prospective clinical study.Early detection of lung cancer, while in its most treatable stage, leads to better clinical outcomes for patients.1,2 Recently, the United States Preventive Services Task Force expanded the recommended ages and smoking history for lung cancer screenings, reaffirming the importance of early detection. In people at high risk for lung cancer, annual screening with a low-dose CT (LDCT) scan is typically recommended as part of the standard of care (SOC)